Kidney-Targeted Delivery of Prolyl Hydroxylase Domain Protein 2 Small Interfering RNA with Nanoparticles Alleviated Renal Ischemia/Reperfusion Injury [0.03%]
纳米颗粒靶向递送脯氨酰羟化酶2小干扰RNA可缓解肾缺血再灌注损伤
Dengpiao Xie,Juan Wang,Gaizun Hu et al.
Dengpiao Xie et al.
Inhibition of hypoxia-inducible factor-prolyl hydroxylase (PHD) has been shown to protect against various kidney diseases. However, there are controversial reports on the effect of PHD inhibition in renoprotection. The present study determi...
Selective Phosphodiesterase 1 Inhibition Ameliorates Vascular Function, Reduces Inflammatory Response, and Lowers Blood Pressure in Aging Animals [0.03%]
选择性磷酸二酯酶1抑制改善血管功能、减少炎症反应和降低老年动物血压
Keivan Golshiri,Ehsan Ataei Ataabadi,Eloísa Rubio-Beltran et al.
Keivan Golshiri et al.
Diminished nitric oxide-cGMP-mediated relaxation plays a crucial role in cardiovascular aging, leading to decreased vasodilation, vascular hypertrophy and stiffening, and ultimately, cardiovascular dysfunction. Aging is the time-related wor...
In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters [0.03%]
维纳鲁司及其代谢产物作为代谢酶和药物转运体底物和抑制剂的药物相互作用潜力的体外评估
V Sashi Gopaul,Anna Vildhede,Tommy B Andersson et al.
V Sashi Gopaul et al.
Verinurad is a selective uric acid transporter 1 (URAT1) inhibitor in development for the treatment of chronic kidney disease and heart failure. In humans, two major acyl glucuronide metabolites have been identified: direct glucuronide M1 a...
Liver-Specific Nonviral Gene Delivery of Fibroblast Growth Factor 21 Protein Expression in Mice Regulates Body Mass and White/Brown Fat Respiration [0.03%]
肝脏特异性的非病毒FGF21基因传递系统对小鼠机体质量和脂肪呼吸代谢的影响研究
Nathaniel G Girer,Victoria G Rontoyanni,Aditya Joshi et al.
Nathaniel G Girer et al.
Viral-mediated in vivo gene delivery methods currently dominate among therapeutic strategies within the clinical and experimental settings, albeit with well documented limitations arising from immunologic constraints. In this study, we demo...
Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects [0.03%]
一项在健康受试者中评估Ipatasertib与伊曲康唑和粪卟啉I和III相互作用的单药相互作用研究的评价
Rucha S Sane,Kit Wun Kathy Cheung,Eunpi Cho et al.
Rucha S Sane et al.
Ipatasertib is a pan-AKT inhibitor in development for the treatment of cancer. Ipatasertib was metabolized by CYP3A4 to its major metabolite, M1 (G-037720), and was a P-gp substrate and OATP1B1/1B3 inhibitor in vitro. A phase I drug-drug in...
Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome" [0.03%]
“Apraglutide:一种新型长效肽类胰高血糖素样肽-2受体激动剂治疗短肠综合征的药理特征”一文的观点性评论
Jolanta Skarbaliene,Bjarne Due Larsen,Mark Berner-Hansen et al.
Jolanta Skarbaliene et al.
A Comparison of Breathing Stimulants for Reversal of Synthetic Opioid-Induced Respiratory Depression in Conscious Rats [0.03%]
比较吸入刺激剂逆转合成阿片类药物诱导的清醒大鼠呼吸抑制的效果
Kaye E Dandrea,Joseph F Cotten
Kaye E Dandrea
Potent synthetic opioids are an important cause of death in the United States' opioid epidemic, and a breathing stimulant may have utility in treating opioid overdose. We hypothesized that sufentanil-induced respiratory depression may be re...
Characterization of Novel Diphenylamine Compounds as Ferroptosis Inhibitors [0.03%]
新型二苯胺衍生物作为铁死亡抑制剂的特性研究
L Hinder,A L Pfaff,R E Emmerich et al.
L Hinder et al.
Ferroptosis is a form of oxidative cell death that is increasingly recognized as a key mechanism not only in neurodegeneration but also in regulated cell death, causing disease in other tissues. In neurons, major hallmarks of ferroptosis in...
Beth Youngblood,Kevin Li,Donald R Gehlert et al.
Beth Youngblood et al.
Opioid use disorder (OUD) is a major socioeconomic burden. An ideal OUD pharmacotherapy will mitigate the suffering associated with opioid-withdrawal, inhibit the effects of high efficacy opioids, and minimize opioid-cravings while being sa...